Boston Scientific Q3 FY26: where the revenue came from and where it went
The whole income statement of Boston Scientific for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
- Reported
- Nov 2, 2026
Revenue$5.14B
+1% year over year
Gross profit$3.43B
67% margin
Operating profit$0.83B
16% margin
Net profit$0.58B
11% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 5.14 | 100% | +1% |
| Cardiology therapies | 1.27 | 25% | |
| Electrophysiology | 0.82 | 16% | −6% |
| Global endoscopy | 0.74 | 14% | −1% |
| Urology & pelvic health | 0.66 | 13% | −3% |
| Cardiac rhythm management | 0.57 | 11% | −2% |
| Watchman | 0.48 | 9% | −6% |
| Neuromodulation | 0.33 | 7% | +13% |
| Interventional oncology | 0.27 | 5% | |
| Cost of revenue | −1.71 | 33% | |
| Gross profit | 3.43 | 67% margin | −3pp |
| SG&A | −1.68 | 33% | −2pp |
| Other | −0.92 | 18% | |
| Operating profit | 0.83 | 16% margin | −5pp |
| Interest & other costs | −0.10 | ||
| Tax | −0.15 | ||
| Net profit | 0.58 | 11% margin | −4pp |
2 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest